Dipòsit Digital de Documents de la UAB 5 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
10 p, 1.6 MB International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting / El-Beshlawy, Amal (Cairo University) ; Inusa, Baba (Evelina Children's Hospital) ; Beneitez Pastor, David (Hospital Universitari Vall d'Hebron. Departament d'Hematologia) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Duran Nieto, Maria Soledad (Hospital Materno Infantil de Jaén) ; Bruederle, Andreas (Novartis Pharma AG) ; Azmon, Amin (Novartis Pharma AG, Switzerland) ; Gilotti, Geralyn (Novartis Pharmaceuticals Corporation, USA) ; Elalfy, Mohsen (Ain Shams University, Cairo) ; Universitat Autònoma de Barcelona
Objective:The study evaluates the long-term deferasirox treatment of adult and pediatricpatients with chronic transfusional iron overload in clinical practice. Methods:In this non-interventional study, patients were observed for up to 3 years frominitiation of deferasirox treatment both prospectively and retrospectively for up to 1 yearprior to enrollment. [...]
2019 - 10.1080/16078454.2018.1558758
Hematology, 2019  
2.
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (Department of Medicine II, Department of Hematology/Oncology, University Hospital, Frankfurt, Germany) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Department of Hematology and Oncology, University Hospital Schleswig-Holstein) ; Doubek, Michael (Department of Internal Medicine, Hematology and Oncology,University Hospital, Brno, Czech Republic) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (Department of Medicine II, Department of Hematology/Oncology, University Hospital, Frankfurt, Germany) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Josep Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  
3.
8 p, 455.0 KB Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer : a phase I/II randomized trial / Moran, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Felip, Enriqueta (Hospital Universitary de la Vall d'Hebron) ; Keedy, Vicki (Vanderbilt University Medical Center) ; Borghaei, Hossein (Fox Chase Cancer Center, Philadelphia) ; Shepherd, Frances A (University of Toronto) ; Insa, Amelia (Hospital Clínico Universitario de Valencia) ; Brown, Holly (Merck & Co., Inc., Whitehouse Station) ; Fitzgerald, Timothy (Merck & Co., Inc., Whitehouse Station) ; Sathyanarayanan, Sriram (Whitehouse Station, NJ USA) ; Reilly, John F (Merck & Co., Inc., Whitehouse Station) ; Mauro, David (Merck & Co., Inc., Whitehouse Station) ; Hsu, Karl (Sanofi Aventis) ; Yan, Li (Merck & Co., Inc., Whitehouse Station) ; Universitat Autònoma de Barcelona
We investigated the safety and antitumor activity of dalotuzumab, a selective anti-insulin growth factor 1 receptor monoclonal antibody (IGF1R MoAb), plus erlotinib in a sequential phase I/II trial in unselected patients with refractory advanced non-small-cell lung cancer (NSCLC). [...]
2014 - 10.1186/2162-3619-3-26
Experimental Hematology & Oncology, Vol. 3 (november 2014)  
4.
9 p, 316.0 KB Treatment of Adolescent and Young Adults with Acute Lymphoblastic Leukemia / Ribera, Josep-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ribera, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
The primary objective of this review was to update and discuss the current concepts and the results of the treatment of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA). After a brief consideration of the epidemiologic and clinicobiologic characteristics of ALL in the AYA population, the main retrospective comparative studies stating the superiority of pediatric over adult-based protocols were reviewed. [...]
2014 - 10.4084/MJHID.2014.052
Mediterranean Journal of Hematology and Infectious Diseases, Vol. 6 (july 2014)  
5.
11 p, 858.6 KB Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation / Baron, Frédéric (Université de Liège (Bèlgica)) ; Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ; Ruggeri, Annalisa (Hôpital Saint-Louis (Paris, França)) ; Mohty, Mohamad (Hôpital Saint-Antoine (Paris, França)) ; Sanz, Guillermo (Hospital Universitario y Politécnico La Fe (València, País Valencià)) ; Milpied, Noel (Hôpital Haut Léveque (Pessac, França)) ; Bacigalupo, Andrea (Ospedale Sant Martino (Genova, Itàlia)) ; Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII (Bergamo, Itàlia)) ; Bonifazi, Francesca (Policlinico Sant'Orsola-Malpighi (Bologna, Itàlia)) ; Bosi, Alberto (Azienda Ospedaliero Universitaria Careggi (Firenze, Itàlia)) ; Sierra, Jorge (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ; Yakoub-Agha, Ibrahim (Hôpital Claude Huriez (Lille, França)) ; Ribera Santasusana, J. M. (José María) (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gluckman, Eliane (Hôpital Saint-Louis (Paris, França)) ; Nagler, Arnon (Sheba Medical Center (Ramat Gran, Israel))
BACKGROUND: In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation, transplanting male patients with grafts from female donors has been associated with a higher incidence of graft-versus-host disease (GVHD) and of nonrelapse mortality (NRM). [...]
2015 - 10.1186/s13045-015-0207-4
Journal of hematology & oncology, Vol. 8 Núm. 107 (october 2015)  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.